Genetic Study Pinpoints ASGR1 as Molecular Link Between Smoking and Heart Disease

Smoking has long been established as one of the most potent modifiable risk factors for ischemic heart disease, yet the precise molecular mechanisms through which cigarette smoke translates into clogged arteries and heart attacks have remained frustratingly opaque. Now, a large-scale proteomic study has brought scientists a significant step closer to an answer. By combining genetic tools with measurements of thousands of circulating proteins, researchers have identified ASGR1 — a protein already known to influence cholesterol levels — as a potential molecular mediator that connects smoking to the development of ischemic heart disease. The findings, published in Nature Cardiovascular Research, suggest that the damaging effects of tobacco smoke on the cardiovascular system may be partly channeled through specific, druggable proteins circulating in the blood.

The research team, led by Tinworth and colleagues, undertook what is known as a proteome-wide genetic analysis. Rather than simply measuring proteins and looking for correlations with disease, the investigators exploited a powerful property of human genetics: each person’s blood protein levels are influenced by naturally occurring genetic variants. Because these variants are inherited randomly and fixed at conception, they are largely immune to the confounding that plagues ordinary observational studies. This approach, often called Mendelian randomization at the proteomic scale, allows scientists to ask whether a protein is merely a bystander in disease or whether it plays a genuine causal role.

The scale of the undertaking was considerable. The researchers drew on genetic and proteomic data from tens of thousands of individuals, quantifying thousands of proteins in blood plasma and then mapping genetic variants that predict the abundance of each one. They then cross-referenced these protein-encoding variants with genetic predictors of smoking behavior — including measures of smoking initiation, lifetime smoking burden, and smoking cessation — as well as with genetic predictors of ischemic heart disease risk. The goal was to find proteins whose genetically determined levels shift in response to smoking exposure and which, in turn, influence the likelihood of developing coronary artery disease.

Among the thousands of proteins screened, one stood out: asialoglycoprotein receptor 1, or ASGR1. This protein, produced primarily in the liver, is a receptor best known to cardiovascular researchers from a striking natural experiment. Individuals carrying loss-of-function mutations in the ASGR1 gene enjoy remarkably low levels of LDL cholesterol and a correspondingly reduced risk of coronary heart disease, a discovery that has already made ASGR1 a target of intense pharmaceutical interest. The new analysis adds a twist to that story: smoking appears to alter circulating levels of ASGR1, and this smoking-driven change may represent one pathway through which tobacco smoke raises the risk of ischemic heart disease.

The technical logic of the analysis deserves closer examination. In a conventional study, smokers differ from non-smokers in dozens of ways — diet, alcohol consumption, socioeconomic background, and countless other factors — making it nearly impossible to isolate the effect of smoking itself. Genetic instruments sidestep this problem. Variants that predict smoking behavior can be used as proxies for smoking exposure, and variants that predict protein levels can be used as proxies for protein abundance. By testing whether the smoking-linked variants associate with disease risk through the protein-linked variants, the researchers could trace a chain of causation from behavior to protein to pathology. Statistical methods such as two-step and mediation Mendelian randomization were applied to formalize this chain and to quantify how much of smoking’s cardiovascular effect might flow through ASGR1.

The results pointed to a meaningful mediating role. Smoking exposure was associated with changes in circulating ASGR1 levels, and genetically predicted alterations in ASGR1 were in turn linked to ischemic heart disease risk, consistent with the protein’s established role in lipid metabolism. While the analysis cannot claim that ASGR1 explains all — or even most — of smoking’s cardiovascular harm, it provides evidence that this receptor sits on a causal pathway connecting tobacco smoke to coronary disease. That distinction matters enormously for drug development. Biomarkers that merely correlate with disease often prove useless as therapeutic targets; proteins that causally mediate risk, by contrast, are precisely the molecules that intervention should aim at.

The findings also resonate with a broader shift in cardiovascular research. For decades, the link between smoking and heart disease was attributed largely to well-characterized mechanisms: carbon monoxide reducing oxygen delivery, oxidative stress damaging blood vessel walls, nicotine raising heart rate and blood pressure, and smoke constituents promoting inflammation and thrombosis. Proteomics adds a new layer to this picture, revealing that smoking leaves a detectable signature across hundreds of circulating proteins, some of which may actively participate in disease rather than simply marking it. Studies of this kind have previously uncovered mediators of inflammation, coagulation, and lipid transport, and the identification of ASGR1 extends that list into territory already being explored by the pharmaceutical industry.

Indeed, the therapeutic implications are among the most compelling aspects of the work. ASGR1 inhibitors are already in development as cholesterol-lowering agents, with several companies pursuing antisense oligonucleotide and antibody approaches designed to mimic the protective effect of natural loss-of-function mutations. If smoking acts partly by pushing ASGR1 in a harmful direction, then drugs that modulate the ASGR1 pathway could, in principle, blunt some of the cardiovascular damage inflicted by tobacco — even in people who continue to smoke or who quit too late to avoid all risk. Such an intervention would not excuse smoking, but it could offer a pharmacological safety net for the hundreds of millions of smokers worldwide who face elevated cardiac risk.

The authors and outside observers alike caution that important questions remain. Mendelian randomization rests on assumptions that can never be fully verified, and mediation analyses of this kind capture only the portion of an effect that flows through genetically influenced protein levels. Smoking damages the heart through many routes, and ASGR1 is unlikely to be the whole story. Validation in independent cohorts, experimental studies of how smoke constituents regulate ASGR1 expression, and ultimately clinical trials of ASGR1-targeted therapies in high-risk populations will all be needed before the biomarker can move from statistical association to clinical practice. Still, the study exemplifies how large-scale proteogenomic data can convert a diffuse behavioral risk factor into a concrete molecular hypothesis.

For the public, the message remains unchanged in its essentials: not smoking is still the single best thing a person can do for their heart. But for researchers and clinicians, the work offers something new — a specific, testable, and potentially druggable molecule that helps explain why cigarettes clog arteries. As proteomic datasets grow and genetic instruments sharpen, studies of this kind are expected to uncover further mediators linking lifestyle exposures to disease, gradually assembling a molecular map of how everyday behaviors shape long-term cardiovascular health. The identification of ASGR1 as a candidate link between smoking and ischemic heart disease is a notable waypoint on that map, and one that the cardiology community will be watching closely.

Subject of Research: Proteome-wide genetic analysis identifying ASGR1 as a molecular mediator linking smoking with ischemic heart disease

Article Title: Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease

Article References: Tinworth, A. C., Yao, P., Iona, A., Pozarickij, A., Von Ende, A., Millwood, I. Y., Walters, R. G., Clarke, R., Bragg, F., & Chen, Z. (2026). Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00871-x

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00871-x

Keywords: ASGR1, smoking, ischemic heart disease, proteomics, Mendelian randomization, biomarker, LDL cholesterol, cardiovascular risk, genetic analysis, coronary artery disease, Proteome-wide, genetic